Physician profile
Daniel D Dugi
NPI 1598701344
$3,126.28
in general payments reported to CMS, 2019-2025
41 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $290 · 2021: $594 · 2022: $367 · 2023: $468 · 2024: $307 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.26 |
| Education | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $315.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $220.87 | 2021-2023 | Linzess |
| Novartis Pharmaceuticals Corporation | $215.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $211.03 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $195.39 | 2019-2023 | Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $178.27 | 2019-2025 | Rexulti |
| Amgen INC. | $158.34 | 2020-2025 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $122.70 | 2020-2021 | |
| Pfizer INC. | $116.97 | 2019-2025 | |
| Axsome Therapeutics, INC. | $115.60 | 2024 | Auvelity |
| Novo Nordisk INC | $112.32 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $109.34 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $108.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.32 | 2021-2024 | Ofev |
| Merck Sharp & Dohme LLC | $72.04 | 2022-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dugi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.